Inhibikase Therapeutics, Inc. Common Stock
$2.30
-$0.01 (-0.43%)
$2.29Day Range$2.37
Key Statistics
Market Cap
$320.93M
Shares Outstanding
139.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 23, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$2.31
Day High
$2.37
Day Low
$2.29
Volume
475.5K
VWAP
$2.31
Prev Close
$2.31
Transactions
--
Acc. Volume
--
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283635 employees1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801(302) 295-3800IPO Dec 23, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001750149
- Composite FIGI
- BBG005TP2339
- Share Class FIGI
- BBG005TP2348
- Ticker Root
- IKT
- SIC Code
- 2836
About Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock
Inhibikase Therapeutics, Inc. Common Stock (IKT) closed the 2026-09-17 session at $2.30, down 0.43% versus the previous close (-0.01). The stock opened at $2.31 and traded between $2.29 and $2.37 during that session. Session trading volume was 476K shares. The volume-weighted average price (VWAP) is $2.31.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Inhibikase Therapeutics, Inc. Common Stock has a market capitalization of $320.9 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. IKT is listed on the XNAS exchange. The company employs approximately 35 people. Inhibikase Therapeutics, Inc. Common Stock is headquartered in WILMINGTON, DE. The recorded listing date is 2020-12-23.
On this page you can find market IKT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.